在新冠病毒疾病管理中使用利托那韦增强型PF-07321332时需谨慎。 - Suppr

Suppr

超能文献

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.

作者信息

Heskin Joseph, Pallett Scott J C, Mughal Nabeela, Davies Gary W, Moore Luke S P, Rayment Michael, Jones Rachael

机构信息

Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.

Royal Defence Medical College, Royal Centre for Defence Medicine, Birmingham, UK.

出版信息

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.

DOI:10.1016/S0140-6736(21)02657-X

PMID:34973713

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8718360/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c1a/8718360/39e3e873a906/fx1_lrg.jpg

相似文献

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.

Nirmatrelvir-ritonavir for COVID-19.

CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.

From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.

JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925.

Audio Interview: A New Antiviral against Covid-19.

N Engl J Med. 2022 Feb 17;386(7):e25. doi: 10.1056/NEJMe2202349.

Bad news for Paxlovid? Resistance may be coming.

Science. 2022 Jul 8;377(6602):138-139. doi: 10.1126/science.add8037. Epub 2022 Jul 7.

Paxlovid for treatment of COVID-19.

Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.

Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.

N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.

An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.

Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.

Antiviral pills could change pandemic's course.

Science. 2021 Nov 12;374(6569):799-800. doi: 10.1126/science.acx9605. Epub 2021 Nov 11.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.

N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.

引用本文的文献

Au(I)-based compounds inhibit nsp14/nsp10 and nsp13 (helicase) to exert anti-SARS-CoV-2 properties.

J Biol Inorg Chem. 2025 Jun 18. doi: 10.1007/s00775-025-02118-9.

Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations.

EPMA J. 2025 Mar 15;16(2):505-517. doi: 10.1007/s13167-025-00402-x. eCollection 2025 Jun.

Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors.

ACS Med Chem Lett. 2025 Apr 14;16(5):790-796. doi: 10.1021/acsmedchemlett.4c00637. eCollection 2025 May 8.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5.

SARS-CoV-2 PL Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment.

ChemistryOpen. 2024 Nov;13(11):e202400091. doi: 10.1002/open.202400091. Epub 2024 Aug 5.

Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.

Heliyon. 2024 May 30;10(11):e32187. doi: 10.1016/j.heliyon.2024.e32187. eCollection 2024 Jun 15.

An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

Int J Mol Sci. 2023 Dec 26;25(1):354. doi: 10.3390/ijms25010354.

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.

EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. eCollection 2024 Jan.

How Deep Learning in Antiviral Molecular Profiling Identified Anti-SARS-CoV-2 Inhibitors.

Biomedicines. 2023 Nov 24;11(12):3134. doi: 10.3390/biomedicines11123134.

Targeted degrader technologies as prospective SARS-CoV-2 therapies.

Drug Discov Today. 2024 Jan;29(1):103847. doi: 10.1016/j.drudis.2023.103847. Epub 2023 Nov 28.

本文引用的文献

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.

HIV Med. 2016 Aug;17 Suppl 4:s2-s104. doi: 10.1111/hiv.12426.

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.

AIDS Rev. 2015 Jan-Mar;17(1):37-46.

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

Trends Pharmacol Sci. 2010 Jan;31(1):22-35. doi: 10.1016/j.tips.2009.10.001. Epub 2009 Dec 11.

Induction effects of ritonavir: implications for drug interactions.

Ann Pharmacother. 2008 Jul;42(7):1048-59. doi: 10.1345/aph.1K615. Epub 2008 Jun 24.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. doi: 10.1093/jac/dkh029. Epub 2003 Dec 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.

作者信息

Heskin Joseph, Pallett Scott J C, Mughal Nabeela, Davies Gary W, Moore Luke S P, Rayment Michael, Jones Rachael

机构信息

Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.

Royal Defence Medical College, Royal Centre for Defence Medicine, Birmingham, UK.

出版信息

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.

DOI:10.1016/S0140-6736(21)02657-X

PMID:34973713

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8718360/

Abstract

摘要

相似文献

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.

Nirmatrelvir-ritonavir for COVID-19.

CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.

From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.

JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925.

Audio Interview: A New Antiviral against Covid-19.

N Engl J Med. 2022 Feb 17;386(7):e25. doi: 10.1056/NEJMe2202349.

Bad news for Paxlovid? Resistance may be coming.

Science. 2022 Jul 8;377(6602):138-139. doi: 10.1126/science.add8037. Epub 2022 Jul 7.

Paxlovid for treatment of COVID-19.

Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.

Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.

N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.

An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.

Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.

Antiviral pills could change pandemic's course.

Science. 2021 Nov 12;374(6569):799-800. doi: 10.1126/science.acx9605. Epub 2021 Nov 11.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.

N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.

引用本文的文献

Au(I)-based compounds inhibit nsp14/nsp10 and nsp13 (helicase) to exert anti-SARS-CoV-2 properties.

J Biol Inorg Chem. 2025 Jun 18. doi: 10.1007/s00775-025-02118-9.

Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations.

EPMA J. 2025 Mar 15;16(2):505-517. doi: 10.1007/s13167-025-00402-x. eCollection 2025 Jun.

Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors.

ACS Med Chem Lett. 2025 Apr 14;16(5):790-796. doi: 10.1021/acsmedchemlett.4c00637. eCollection 2025 May 8.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5.

SARS-CoV-2 PL Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment.

ChemistryOpen. 2024 Nov;13(11):e202400091. doi: 10.1002/open.202400091. Epub 2024 Aug 5.

Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.

Heliyon. 2024 May 30;10(11):e32187. doi: 10.1016/j.heliyon.2024.e32187. eCollection 2024 Jun 15.

An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

Int J Mol Sci. 2023 Dec 26;25(1):354. doi: 10.3390/ijms25010354.

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.

EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. eCollection 2024 Jan.

How Deep Learning in Antiviral Molecular Profiling Identified Anti-SARS-CoV-2 Inhibitors.

Biomedicines. 2023 Nov 24;11(12):3134. doi: 10.3390/biomedicines11123134.

Targeted degrader technologies as prospective SARS-CoV-2 therapies.

Drug Discov Today. 2024 Jan;29(1):103847. doi: 10.1016/j.drudis.2023.103847. Epub 2023 Nov 28.

本文引用的文献

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.

HIV Med. 2016 Aug;17 Suppl 4:s2-s104. doi: 10.1111/hiv.12426.

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.

AIDS Rev. 2015 Jan-Mar;17(1):37-46.

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

Trends Pharmacol Sci. 2010 Jan;31(1):22-35. doi: 10.1016/j.tips.2009.10.001. Epub 2009 Dec 11.

Induction effects of ritonavir: implications for drug interactions.

Ann Pharmacother. 2008 Jul;42(7):1048-59. doi: 10.1345/aph.1K615. Epub 2008 Jun 24.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. doi: 10.1093/jac/dkh029. Epub 2003 Dec 4.